Google

Archive for the ‘Bones / Orthopaedics’ Category

Protelos(R) (Strontium Ranelate) Is The First Osteoporosis Treatment To Demonstrate Long-term Reduced Risk Of Hip Fracture

Sunday, July 13th, 2008

Results of a new study published in the latest edition of leading journal Arthritis and Rheumatism confirm a long-term reduction in the risk of fractures with strontium ranelate in post menopausal women with osteoporosis. The trial, which studied the efficacy of strontium ranelate over a five year period, showed significant ...

Pseudotumours Risk For Hip Resurfacing Highlights Need For Regular Clinical Follow-up For New Devices

Saturday, July 12th, 2008

As the incidence of metal-on-metal hip resurfacing has increased in recent years, especially in younger patients, research published in the Journal of Bone and Joint Surgery - British Volume (JBJS-Br) discusses occurrences of "pseudotumours" as a result. The researchers estimate that approximately 1% of patients who have metal-on-metal hip resurfacings ...

Returning To Sport After Joint Replacement

Friday, July 11th, 2008

Research published in the Journal of Bone and Joint Surgery-British Volume (JBJS-Br), demonstrates that a majority of those who were actively participating in sport before a joint replacement or resurfacing were able to return to sport after their operation. A total of 61.4% of patients surveyed had returned to sport ...

NICE Final Recommends Treatment Options For Primary, Secondary Prevention Of Osteoporotic Fragility Fractures In Postmenopausal Women, UK

Thursday, July 10th, 2008

Procter & Gamble Pharmaceuticals (P&GP) welcome the new Final Appraisal Determination (FAD) Guidance for the primary and secondary prevention of osteoporosis from NICE. The revised NICE FAD recommends risedronate - alongside etidronate - as the first alternative treatment option to generic alendronate for postmenopausal women who are unable to comply ...

Epeius Biotechnologies’ Tumor Targeted Rexin G Receives FDA Orphan Drug Designation For The Treatment Of Osteosarcoma

Thursday, July 10th, 2008

Epeius Biotechnologies Corporation announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Based on several criteria, including the rarity, seriousness, and current lack of effective therapies for metastatic osteosarcoma, as well as the scientific and medicinal merit ...

A New Frontier In The Battle Against Disc Degeneration

Thursday, July 10th, 2008

Many individuals experience back pain arising from discs that are no longer healthy. The condition is often referred to as painful disc degeneration, and it is a common problem. A review article published in the June 2008 issue of the Journal of the American Academy of Orthopaedic Surgeons discusses how ...

NICE Fails To Act On Risk Of Fracture, Says Osteoporosis Charity, UK

Thursday, July 10th, 2008

The National Institute for Health and Clinical Excellence (NICE) will publish their latest appraisal of osteoporosis drugs which, according to the National Osteoporosis Society has failed to overcome the problems that resulted in a successful appeal last year.Almost a year to the day that the charity launched an appeal ...

New Drug Prevents Dangerous Complications Of Hip And Knee Surgery, Says McMaster Professor

Friday, June 27th, 2008

A McMaster University researcher predicts a new oral blood thinner will revolutionize treatment for preventing dangerous blood clots in patients undergoing hip and knee surgery. Dr. Alexander Turpie, professor of medicine in the Michael G. DeGroote School of Medicine, oversaw four major international studies on the drug rivaroxaban (Xarelto).All studies ...

ArthroCare Launches DoublePlay™ New Osteoconductive Suture Anchor

Thursday, June 26th, 2008

ArthroCare® Corp. (NASDAQ: ARTC) announced the launch of its new DoublePlay implant, a novel suture anchor device intended for soft tissue to bone fixation in surgical procedures such as rotator cuff repair. It is unique in terms of design and material. The DoublePlay device is a fully threaded anchor and ...

Mechanism Uncovered That Contribues To The Appropriate Formation Of The Spine

Sunday, June 22nd, 2008

The Stowers Institute's Pourquie Lab has shed light on the mechanism causing animals to develop the appropriate number of vertebrae.Vertebrae are formed from their embryonic precursors, called somites. The number of somites is consistent within a species, but varies significantly across species. By comparing the developing embryos of zebrafish, chicken, ...

Topical NSAID As Effective As Tablets For Knee Pain

Friday, June 20th, 2008

Research published by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme has found that non-steroidal anti-inflammatory (NSAIDs) creams is as effective as tablets for the treatment of chronic knee pain in older people. Currently both topical and oral NSAID preparations of drugs like ibuprofen, ...

International Osteoporosis Foundation Announces Three Orthopaedic Sessions At 2008 Congress

Monday, June 16th, 2008

The International Osteoporosis Foundation has announced expanded opportunities for orthopaedic surgeons at the IOF World Congress on Osteoporosis 2008, to be held in Bangkok, Thailand, from December 3-7 2008. At three dedicated orthopaedic sessions, details below, orthopaedic surgeons can meet international experts to discuss specific clinical challenges and learn how ...

First New Oral Anticoagulant In More Than 40 Years Approved In Canada

Sunday, June 15th, 2008

Boehringer Ingelheim Canada Ltd. today announced that Health Canada has granted marketing authorization of PRADAX™ (dabigatran etexilate), a novel oral direct thrombin inhibitor (DTI) for the prevention of venous thromboembolism (VTE) in adult patients who have undergone elective total hip or total knee replacement surgery. The approval of PRADAX™ ...

New Data Demonstrates Joint Damage Is Inhibited With Wyeth’s Biologic Enbrel(R) Plus Methotrexate In Patients With Early Active Rheumatoid Arthritis

Saturday, June 14th, 2008

Study Results Provide Further Evidence That Early Treatment of Rheumatoid Arthritis With Enbrel(R) Plus Methotrexate in Moderate to Severe Patients can Stop the Disease From Progressing, and Helps Patients Return to More Normal and Productive Lives ...

GE Healthcare Clinical Systems Lunar Gets Top Ranking In Bone Mineral Densitometry Customer Satisfaction

Saturday, June 14th, 2008

In its latest report on bone mineral densitometry equipment, MD Buyline, an independent medical technology and informatics intelligence firm, has ranked GE Healthcare number one for the second consecutive quarter. Not only did GE Healthcare's GE Lunar bone mineral densitometry products achieve the highest overall user satisfaction composite rating from ...